Piramal Pharma Solutions, George Medicines develop new hypertension drug Widaplik

George Medicines and Piramal Pharma Solutions began their collaboration on WIDAPLIK in December 2018, when the formulation was developed at Piramal's Pharmaceutical Development site in Ahmedabad, India. In June 2020, the project was transferred to Piramal's drug product facility in Pithampur, India for validation and manufacturing. George Medicines achieved FDA approval for WIDAPLIK this year.

"This achievement highlights the value that Piramal Pharma Solutions delivers to its clients and the patients they serve," said Peter DeYoung, CEO, Piramal Global Pharma. "We are excited to deepen our collaboration with George Medicines, expanding access to transformative treatment options like WIDAPLIK to support our mission and enhance patient outcomes on a global scale."

"Our strategic partnership with Piramal Pharma Solutions has been an important part of the success to date of WIDAPLIK," added Mark Mallon, CEO, George Medicines. "Globally, more than one billion adults have hypertension, and it remains a major cause of premature death worldwide. With its triple combination efficacy, multiple dosing options, including two doses that are lower than those currently available in single pill combinations, and its established safety profile, WIDAPLIK has the potential to change the hypertension treatment paradigm. Piramal Pharma Solutions is an excellent development and manufacturing partner on this program who brings capacity, know-how, and shares our commitment to affordability, access, and quality, and we look forward to the continuation of our strong partnership."